3M Licenses Fentanyl Transdermal Patch Technology
3M Drug Delivery Systems recently announced that STADA Arzneimittel AG has become the latest drug company to license 3M’s patented technology directed to a matrix patch for the transdermal delivery of the opioid pain medication fentanyl. Terms of the license agreement were not disclosed.
The 3M Patent (EP 2158905), which was granted on March 20, 2013, enables a transdermal drug delivery device designed to deliver a therapeutically effective amount of fentanyl across the skin of a patient. The matrix device is configured by incorporating fentanyl into an adhesive matrix made of a copolymer containing alkyl acrylate and other monomers. 3M is open to licensing this technology to other interested parties.
STADA Arzneimittel AG is a publicly listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. For more information, visit www.stada.com.
3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M’s inhalation, transdermal, or microneedle drug delivery technology. 3M offers a full range of feasibility, development, and manufacturing capabilities to help bring products to market. Regulatory expertise, quality assurance, operations, marketed product support, and other in-house resources are available for each step of the development and commercialization process. For more information, visit www.3M.com/dds or call 1-800-643-8086.
Total Page Views: 2262
